Shandong Buchang Pharmaceuticals Co Ltd (603858) - Total Assets
Based on the latest financial reports, Shandong Buchang Pharmaceuticals Co Ltd (603858) holds total assets worth CN¥19.57 Billion CNY (≈ $2.86 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Shandong Buchang Pharmaceuticals Co Ltd - Total Assets Trend (2011–2024)
This chart illustrates how Shandong Buchang Pharmaceuticals Co Ltd's total assets have evolved over time, based on quarterly financial data. Also see how much is Shandong Buchang Pharmaceuticals Co Ltd worth for the company's overall valuation and market capitalisation.
Shandong Buchang Pharmaceuticals Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Shandong Buchang Pharmaceuticals Co Ltd's total assets of CN¥19.57 Billion consist of 39.0% current assets and 61.0% non-current assets. Review Shandong Buchang Pharmaceuticals Co Ltd debt and liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 4.2% |
| Accounts Receivable | CN¥1.37 Billion | 7.1% |
| Inventory | CN¥4.62 Billion | 23.9% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥2.49 Billion | 12.9% |
| Goodwill | CN¥620.04 Million | 3.2% |
Asset Composition Trend (2011–2024)
This chart illustrates how Shandong Buchang Pharmaceuticals Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See current stock price of Shandong Buchang Pharmaceuticals Co Ltd for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shandong Buchang Pharmaceuticals Co Ltd's current assets represent 39.0% of total assets in 2024, a decrease from 77.0% in 2011.
- Cash Position: Cash and equivalents constituted 4.2% of total assets in 2024, down from 33.6% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 15.0% of total assets, an increase from 5.0% in 2011.
- Asset Diversification: The largest asset category is inventory at 23.9% of total assets.
Shandong Buchang Pharmaceuticals Co Ltd Competitors by Total Assets
Key competitors of Shandong Buchang Pharmaceuticals Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Torrent Pharmaceuticals Limited
NSE:TORNTPHARM
|
India | Rs443.12 Billion |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Beijing Tongrentang Co Ltd
SHG:600085
|
China | CN¥29.95 Billion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
|
Harbin Pharmaceutical Group Co Ltd
SHG:600664
|
China | CN¥14.08 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Zhejiang Medicine Co Ltd
SHG:600216
|
China | CN¥14.18 Billion |
Shandong Buchang Pharmaceuticals Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.15 | 1.24 | 1.02 |
| Quick Ratio | 0.49 | 0.51 | 0.67 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.01 Billion | CN¥1.47 Billion | CN¥172.57 Million |
Shandong Buchang Pharmaceuticals Co Ltd - Advanced Valuation Insights
This section examines the relationship between Shandong Buchang Pharmaceuticals Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.65 |
| Latest Market Cap to Assets Ratio | 0.12 |
| Asset Growth Rate (YoY) | -7.5% |
| Total Assets | CN¥19.33 Billion |
| Market Capitalization | $2.28 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Shandong Buchang Pharmaceuticals Co Ltd's assets below their book value (0.12x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Shandong Buchang Pharmaceuticals Co Ltd's assets decreased by 7.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Shandong Buchang Pharmaceuticals Co Ltd (2011–2024)
The table below shows the annual total assets of Shandong Buchang Pharmaceuticals Co Ltd from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥19.33 Billion ≈ $2.83 Billion |
-7.48% |
| 2023-12-31 | CN¥20.89 Billion ≈ $3.06 Billion |
-4.83% |
| 2022-12-31 | CN¥21.95 Billion ≈ $3.21 Billion |
-8.48% |
| 2021-12-31 | CN¥23.99 Billion ≈ $3.51 Billion |
+4.80% |
| 2020-12-31 | CN¥22.89 Billion ≈ $3.35 Billion |
+8.03% |
| 2019-12-31 | CN¥21.19 Billion ≈ $3.10 Billion |
+5.79% |
| 2018-12-31 | CN¥20.03 Billion ≈ $2.93 Billion |
+4.31% |
| 2017-12-31 | CN¥19.20 Billion ≈ $2.81 Billion |
+2.79% |
| 2016-12-31 | CN¥18.67 Billion ≈ $2.73 Billion |
+18.47% |
| 2015-12-31 | CN¥15.76 Billion ≈ $2.31 Billion |
+73.16% |
| 2014-12-31 | CN¥9.10 Billion ≈ $1.33 Billion |
+31.18% |
| 2013-12-31 | CN¥6.94 Billion ≈ $1.02 Billion |
+22.43% |
| 2012-12-31 | CN¥5.67 Billion ≈ $829.43 Million |
+27.61% |
| 2011-12-31 | CN¥4.44 Billion ≈ $649.96 Million |
-- |
About Shandong Buchang Pharmaceuticals Co Ltd
Shandong Buchang Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of medicines in China. It offers medicines to treat cardiac and cerebral vascular, urinary and digestive, respiratory, gynecological, and other diseases, as well as diabetes. The company was founded in 1993 and is based in Heze, China.